ESC 2024: Sacubitril/valsartan continues to impress in heart failure - Clinical Trials Arena
Dr. Atsushi Tanaka presented the Premier study findings at ESC, showing sacubitril/valsartan (Sac/Val) prompts greater N-terminal pro-brain natriuretic peptide reduction in Japanese acute HF patients without increased adverse events. Key opinion leaders emphasize Sac/Val's use in hospitalized HF patients, considering its revolutionary impact in reducing cardiovascular deaths and hospitalizations. Launched as Entresto in 2015, Sac/Val's efficacy in acute HF management represents a significant opportunity.
Reference News
Dr. Atsushi Tanaka presented the Premier study findings at ESC, showing sacubitril/valsartan (Sac/Val) prompts greater N-terminal pro-brain natriuretic peptide reduction in Japanese acute HF patients without increased adverse events. Key opinion leaders emphasize Sac/Val's use in hospitalized HF patients, considering its revolutionary impact in reducing cardiovascular deaths and hospitalizations. Launched as Entresto in 2015, Sac/Val's efficacy in acute HF management represents a significant opportunity.